

Special Issue

Molecular Biology and Treatment of Genodermatoses

Message from the Guest Editor

Genodermatoses, a heterogeneous group of congenital skin diseases, are considered to be rare disorders. Recent advances in elucidating the molecular basis of such diseases have contributed to early diagnosis, paving the way to innovative therapeutic approaches, e.g., protein replacement and gene therapies. A better molecular understanding of genodermatoses biology may also provide clues to genetic conditions that do not affect the skin primarily, but are associated with characteristic and clinically significant cutaneous symptoms. This Special Issue will focus on translational research and clinical trials aimed at improving the lives of patients with hereditary ichthyoses, phakomatoses, increased skin fragility, photosensitivity, skin tumorigenesis, cutis laxa, or defective skin appendages. We welcome original research, review articles, opinions, clinical trial protocols or findings of clinical trials, and encourage both scientists and clinicians to share their points of view.

Guest Editor

Prof. Dr. Holm Schneider

Center for Ectodermal Dysplasias & Department of Pediatrics,
University Hospital Erlangen, Loschgestr. 15, 91054 Erlangen, Germany

Deadline for manuscript submissions

closed (1 October 2022)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.9
Indexed in PubMed



mdpi.com/si/118100

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.9
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))